| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| Other Sizes |
| Targets |
The primary target of Cyclo(Arg-Pro) TFA is chitinase, an enzyme that degrades chitin, a major component of fungal cell walls and exoskeletons of insects and crustaceans. As a chitinase inhibitor, it plays a role in modulating cell separation and morphological transitions in fungi, making it a valuable probe in microbiology and cell biology.
|
|---|---|
| ln Vitro |
In vitro, Cyclo(Arg-Pro) TFA inhibits the cell separation of Saccharomyces cerevisiae, leading to the formation of grape-like cell clusters, without affecting cell growth. It also blocks the morphological transition of Candida albicans from the yeast form to the filamentous (hyphal) form without inhibiting growth, demonstrating its specific activity against fungal chitinases.
|
| ln Vivo |
In vivo activity is not applicable as this compound is primarily an in vitro biochemical reagent. It is not administered to animals as a therapeutic agent. Its utility lies in its use as a chemical probe to study fungal biology and chitinase function.
|
| Enzyme Assay |
Not applicable for receptor binding. For chitinase inhibition assays, the enzyme is incubated with Cyclo(Arg-Pro) TFA and a fluorogenic substrate such as 4-methylumbelliferyl beta-D-N,N',N'‘-triacetylchitotriose. The fluorescence (Ex/Em 360/460 nm) is measured over time to calculate IC₅0 values.
|
| Cell Assay |
For cellular assays, yeast cells (Saccharomyces cerevisiae) or Candida albicans cultures are treated with Cyclo(Arg-Pro) TFA (typically 1-100 uM) for 24-48 hours. Cell separation and morphological changes are observed under light microscopy. Cell growth is assessed by OD₆00 measurement to confirm lack of cytotoxicity.
|
| Animal Protocol |
In vivo animal experiments are not standard for this compound. If required, the compound could be used in murine models of fungal infection to assess whether inhibition of chitinase disrupts fungal colonization. Such studies are not commonly performed.
|
| ADME/Pharmacokinetics |
Cyclo(Arg-Pro) TFA is a peptide and is expected to have short half-life in vivo due to rapid proteolytic degradation if not protected. Its cyclic structure confers resistance to exopeptidases, making it more stable in biological matrices than linear peptides. Not for systemic administration.
|
| Toxicity/Toxicokinetics |
Toxicity is minimal at the concentrations used for research (1-100 uM). Standard laboratory safety precautions for peptides should be applied. Avoid inhalation and contact with skin/eyes. Use personal protective equipment. Not for human use.
|
| References | |
| Additional Infomation |
Cyclo(Arg-Pro) TFA is a research tool for studying chitinase function, fungal biology, and peptide stability. It is not an FDA-approved drug and has no clinical indications. It is for research use only, not for human or diagnostic applications. Store at -20degC, protected from light.
|
| Molecular Formula |
C13H20F3N5O4
|
|---|---|
| Molecular Weight |
367.32
|
| Appearance |
White to off-white solid powder
|
| Synonyms |
Cyclo(Pro-Arg) TFA
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~100 mg/mL (~272.24 mM; with ultrasonication)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7224 mL | 13.6121 mL | 27.2242 mL | |
| 5 mM | 0.5445 mL | 2.7224 mL | 5.4448 mL | |
| 10 mM | 0.2722 mL | 1.3612 mL | 2.7224 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
